José Baselga Research Fund Announces First-Ever Grant to Advance Prion Disease Research
The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, today announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders.
JBRF was created by the Baselga family in memory of Dr. José Baselga, a physician-scientist who dedicated his life to the advancement of cancer therapy before passing away two years ago today from Creutzfeldt-Jakob Disease (CJD), an extremely rare, fatal neurodegenerative condition. The Baselga Grant will honor Jose’s legacy and support scientists in the pursuit of understanding, and eradicating, prion diseases such as CJD.
“Our family feels incredibly lucky to have had such an amazing father and husband for as long as we did, and we are committed to continuing his legacy of improving people’s lives through innovative medicines,” commented Clara Baselga-Garriga, daughter of José and student at Harvard Medical School. “We now join in his passion for scientific discovery and are grateful to be partnering with Alexion to support meaningful research for prion diseases on a global scale.”
Each year, the Baselga Grant will support one innovative project by an investigator conducting basic, translational, clinical, or population research. The project must have direct applicability and relevance to understanding the pathophysiology or other aspects of prion diseases, developing therapies, or mechanisms for earlier detection of prion disease. There are no geographic requirements for applicants. The schedule for application submission and review by a renowned advisory board is as follows:
- Letter of Intent Deadline: June 16, 2023
- Notification of Finalists: July 17, 2023
- Final Application Deadline: September 29, 2023
- Notification of Grant Recipient: December 1, 2023
- Initiation of Grant: January 15, 2024
For more information on the Baselga Grant, including submission instructions, additional eligibility guidelines, and evaluation criteria, please visit: http://bit.ly/3Tt7mMG
About Prion Disease
Prion diseases are a group of rare, neurodegenerative disorders that are transmissible, untreatable, and fatal.1 These diseases occur when a normal protein, for unknown reasons, malfunctions and assembles into structured aggregates called prions that cause infectious brain disease.1 The malfunction and assembly process can be underway for years before symptoms appear.1 The best-known prion disease is Creutzfeldt-Jakob Disease (CJD).1 In about 85% of patients, CJD occurs as a sporadic disease with no recognizable pattern of transmission.2 There are currently no effective therapies approved for the treatment of CJD and the vast majority of CJD patients will not live past one year of the onset of illness.2
About the José Baselga Research Fund
Following the death of renowned physician-scientist, Dr. José Baselga, the Baselga family began working alongside Alexion, AstraZeneca Rare Disease, and Charities Aid Foundation to create the “José Baselga Research Fund” to honor José’s legacy and push the science forward in understanding and treating rare neurogenerative conditions, such as prion disease. Each year, this Fund will award the Baselga Grant, consisting of $75,000, to support meaningful clinical or basic science research related to prion disease on a global scale. For more information, please visit: Home | José Baselga
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. For more information, please visit www.alexion.com.
- National Institute of Allergy and Infectious Disease. Prion Diseases. Available here. Access March 2023.
- Centers for Disease Control and Prevention. About CJD, Available here. Accessed March 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005359/en/
Rachel Girard: email@example.com
About Business Wire
24 Martin Lane
EC4R 0DR London
+44 20 7626 1982http://www.businesswire.co.uk
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verisign Reports Internet Has 354.0 Million Domain Name Registrations at the End of the First Quarter of 20238.6.2023 22:55:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the first quarter of 2023 closed with 354.0 million domain name registrations across all top-level domains (TLDs), an increase of 3.5 million domain name registrations, or 1.0%, compared to the fourth quarter of 2022.1,2 Domain name registrations also increased by 3.5 million, or 1.0%, year over year.1,2 The .com and .net TLDs had a combined total of 174.8 million domain name registrations in the domain name base3 at the end of the first quarter of 2023, an increase of 1.0 million domain name registrations, or 0.6%, compared to the fourth quarter of 2022. The .com and .net TLDs had a combined increase of 0.1 million domain name registrations, or 0.1%, year over year. As of March 31, 2023, the .com domain name base totaled 161.6 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net
Momcozy Introduces the Revolutionary M5 All-in-one Hands-free Breast Pump - Empowering Busy Moms with the Ultimate Maternity Solution8.6.2023 22:00:00 CEST | Press release
Momcozy, the esteemed maternity and baby brand favored by over two million moms worldwide, proudly unveils the revolutionary M5 all-in-one hands-free breast pump. Designed to provide the ultimate pumping experience for busy breastfeeding moms, this cutting-edge device showcases Momcozy's commitment to meeting the needs of mothers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005079/en/ M5 All-in-one Handsfree Breast Pump (Graphic: Business Wire) Renowned for its position as a leader in the North American electric breast pump market, Momcozy distinguishes itself yet again with the M5 all-in-one hands-free breast pump. Driven by a user research team that believes in "cozy designs born from love" and strives to cater to customer needs, Momcozy has conducted extensive interviews with thousands of mothers over the past two years. The team's latest findings highlight "comfort" as the most frequently mentioned req
Mouser Electronics Explores the Intersection of Smart-Home Tech with Matter Protocol in Empowering Innovation Together Series8.6.2023 19:08:00 CEST | Press release
Mouser Electronics Inc., the industry's leading New Product Introduction (NPI) distributor with the widest selection of semiconductors and electronic components™, launches the next installment of their award-winning Empowering Innovation Together (EIT) series highlighting the Matter protocol. With this installment, Mouser brings together global technology experts from the Connectivity Standards Alliance (CSA) and industry-leading manufacturers to explore all aspects of Matter, from market introduction to design specifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005018/en/ Matter: One protocol for them all. (Graphic: Business Wire) With its widespread industry support from leading semiconductor manufacturers, including NXP Semiconductors, Silicon Labs, STMicroelectronics, Schneider Electric, Texas Instruments, Infineon Technologies, Nordic Semiconductor and Microchip Technology Inc., Matter promises to revol
Edwards Lifesciences: Improving Patient Safety and Outcomes: EU-HYPROTECT Registry Demonstrates Reduced Time in Hypotension During Surgery Using Acumen HPI Software8.6.2023 18:30:00 CEST | Press release
Edwards Lifesciences today announced the results of the EU-HYPROTECT registry which indicates that using Acumen HPI software may help reduce the duration and severity of intraoperative hypotension in patients having non-cardiac surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005565/en/ (Graph: Business Wire) EU-HYPROTECT is a European multicenter prospective observational registry which included in its final analysis 702 patients scheduled for elective major non-cardiac surgery in 12 medical centers in 5 countries (France, Germany, Italy, Spain, UK). It is the first multicenter registry involving a predictive monitoring technology, establishing a large, prospectively collected data base on hypotension management in patients having non-cardiac surgery. All patients had intraarterial blood pressure monitoring with an arterial catheter and intraoperative Acumen HPI software. Both the duration and severity of intra
Mary Kay Celebrates Oceans Week by Reaffirming Partnership With the Nature Conservancy8.6.2023 18:02:00 CEST | Press release
Mary Kay is celebrating Ocean’s Week by reaffirming its decades-long partnership with The Nature Conservancy (TNC) to support ocean conservation and coral reef protection. Coral reefs, often referred to as the rainforests of the sea, cover less than 1% of the world’s surface area but support 25% of all marine life and over one billion people. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005582/en/ Dr. Elizabeth McLeod, The Nature Conservancy’s Global Oceans Director, conducting research in Ulong Channel, Palau as part of the Super Reefs project, a collaborative effort to discover the secrets of “super reefs” with support from Mary Kay. (Credit: © Kip Evans/CCC Marketing) Because traditional reef conservation strategies have not been enough to counter the global loss of coral reefs, Mary Kay, a signatory to the UN Global Compact Sustainable Ocean Principles, is supporting experts from TNC, Woods Hole Oceanographic Ins